Epidemiological studies have investigated the association between vitamin D pathway genes and breast cancer risk; however, little is known about the association between vitamin D pathway genes and breast cancer prognosis. In a retrospective cohort of 1029 patients with early-stage breast cancer, we analyzed the association between 106 tagging single nucleotide polymorphisms (SNPs) in eight vitamin D pathway genes and breast cancer disease-free survival (DFS) using Cox regression analysis adjusted for known prognostic variables. Using a false discovery rate of 10%, six intronic SNPs were significantly associated with poorer DFS: retinoid-X receptor alpha (RXRA) SNPs (rs881658, rs11185659, rs10881583, rs881657 and rs7864987) and plasminogen activator and urokinase receptor (PLAUR) SNP (rs4251864). Treatment received (no systemic therapy, hormone therapy alone or chemotherapy) was an effect modifier of the RXRA SNPs association with DFS (P < 0.05); therefore, we stratified further analysis by treatment group. Among patients who did not receive systemic therapy, RXRA SNP [rs10881583 (P = 0.02)] was associated with poorer DFS, and among patients who received chemotherapy, RXRA SNPs (rs881658, rs11185659, rs10881583, rs881657 and rs7864987) were associated with poorer DFS (P < 0.001 for all SNPs). However, RXRA SNPs: rs10881583 (P < 0.001) and rs881657 (P = 0.02) were associated with improved DFS in patients treated with hormone therapy alone. Our results suggest that SNPs in the RXRA and PLAUR genes in the vitamin D pathway may contribute to breast cancer DFS. In particular, SNPs in RXRA may predict for poorer or improved DFS in patients, according to type of systemic treatment received. If validated, these markers could be used for risk stratification of breast cancer patients.
Introduction
Breast cancer accounts for 30% of all cancers among women in the USA, and it is estimated that in 2012, there will be 229 060 new cases of breast cancer diagnosed and 39 920 deaths from the disease (1) . Although breast cancer mortality has been declining, recurrence rates are 11% at 5 years and 20% at 10 years after the completion of adjuvant therapy (2) . Vitamin D has been examined as a potential modifier of breast cancer risk and prognosis because of its antitumorigenic and immunomodulatory effects seen in cellular and mouse models (3, 4) . The active form of vitamin D modulates cell growth, differentiation and apoptosis in a number of cell types, including breast cancer cells (5) .
The Goodwin et al. (7) studied a prospective cohort of women with early breast cancer and reported that women with deficient vitamin D levels (<50 nmol/l) had increased risks of distant recurrence and death. Similarly, Vrieling et al. (8) found in a prospective cohort study in Germany that lower serum 25(OH)D concentrations (<35 nmol/l) may be associated with poorer overall survival and distant disease-free survival (DFS) in postmenopausal breast cancer patients. A study in Korean breast cancer patients further confirmed that women with deficient 25(OH)D levels were at increased risk of recurrence compared with those with sufficient vitamin D levels (9) . Lower serum vitamin D levels in breast cancer patients were also found to be associated with later stage of disease (10, 11) and tumor size (12) . Hatse et al. (12) also observed an association of favorable vitamin D status with improved breast cancer-specific outcomes in postmenopausal breast cancer patients. In contrast, two studies have not found an association between vitamin D and breast cancer recurrence (13) or mortality (14) . It is possible that the association between vitamin D levels and breast cancer recurrence may be modified by common genetic variants in vitamin D pathway genes, which could explain some of the inconsistency across studies. Few studies have investigated the association between vitamin D pathway single nucleotide polymorphisms (SNPs) and breast cancer prognosis. In a small study of 111 premenopausal breast cancer patients, Lundin et al. (15) examined the association of a single VDR: Taq1 SNP with overall survival and lymph node metastasis and reported an increased risk of lymph node metastasis for women carrying the VDR Taq1: TT genotype. Hatse et al. (12) analyzed eight SNPs in genes that influence vitamin D levels but did not observe any association with breast cancer outcomes.
We investigated common variants of eight genes in the vitamin D pathway and major metabolites based on their biological role in vitamin D metabolism and signaling (16) 
Materials and methods

Study population
The study population was a retrospective cohort of women diagnosed with early-stage breast cancer (American Joint Committee on Cancer pathologic stage I or II) and treated surgically at The University of Texas MD Anderson Cancer Center between 1985 and 2000. The women were part of the Early Stage Breast Cancer Repository cohort, and criteria for eligibility and cohort details have been described previously (17) . Briefly, patients were eligible for inclusion in the Early Stage Breast Cancer Repository if they were female, were residents of the state of Texas, had surgical treatment for their breast cancer at MD Anderson Cancer Center with tissue available and had complete ascertainment of their medical record. These criteria were established to ensure long-term disease follow-up. The study population for the Early Stage Breast Cancer Repository consisted of 2409 breast cancer patients. Demographic and clinical data were abstracted from medical charts and included age at diagnosis, diagnosis date, tumor size, lymph node status, nuclear grade, estrogen receptor (ER) and progesterone receptor (PR) status, and treatment, including surgery, radiation therapy, chemotherapy, endocrine therapy, tumor type (ductal or lobular), tumor size, lymph node positive, type We selected all African American (n = 196) and Hispanic patients (n = 208) and a random sample of non-Hispanic White patients (n = 986). Of these, 301 patients were excluded because of DNA extraction failure, a further 54 patients were excluded from the study analysis because of genotyping assay failure, and 6 patients were excluded because of no follow-up after diagnosis. Thus, the final study analysis was based on 1029 patients. All participants provided informed consent, and the study was approved by the MD Anderson Institutional Review Board.
DNA extraction, SNP selection and genotyping
Genomic DNA was extracted from peripheral blood using the QIAamp DNA Blood Maxi kit (QIAGEN) according to the manufacturer's instructions (18) . Genomic DNA was extracted from FFPE lymph node tissue using the Applied Biosystems Pico-Pure DNA extraction kit (19) . The call rates for the FFPE samples and buccal or blood samples were 92% and 99%, respectively. We selected variants of eight genes in the vitamin D pathway and major metabolites based on their biological role in vitamin D metabolism and signaling: VDR, GC, RXRA, CYP27B1, CYP24A1, C10orf55, PLAU and PLAUR. Tag SNPs were selected within the genes and in a 2-kb flanking region of each gene using data from the HapMap Project (www.hapmap.org, version 23), applying the approach developed by Carlson et al. (20) . Tag SNP selection was performed in-house at Illumina using an internal script called TagSelector. Inclusion criteria for the SNPs were minor allele frequency ≥0.05, Illumina design score >0.4 and r 2 > 0.8 for binning. Genotyping of the 106 selected tag SNPs was performed on the Illumina GoldenGate platform as part of a larger array of 1536 SNPs. For quality control, 5% duplicate samples (blinded to the laboratory personnel) were included in the array platform; the duplicate concordance was 100%. All genotyping clustering was performed using GenomeStudio data analysis software (Illumina).
Statistical methods
Cox proportional hazards regression analysis was used to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for the association between demographics, clinical and genetic variables, and DFS. The primary study endpoint of DFS time was calculated from the date of first treatment to the date of breast cancer recurrence or date of death due to breast cancer, whichever came first. All other patients were censored at the date of last follow-up or end of the study period. We did not exclude SNPs that violated Hardy-Weinberg Equilibrium from the analysis as the sample consisted of only cancer cases. Each SNP was evaluated for an association with DFS in an additive univariate model and then adjusted for the clinical covariates that were significantly associated with DFS at P < 0.05. Clinical variables examined were age at diagnosis, stage, nuclear grade, body mass index (BMI) measured at registration (BMI categories defined as follows: <25 = normal; 25-30 = overweight; >30 = obese), ER and PR status (ER or PR ≥10% = positive; <10% = negative), race (White, African American and Hispanic) and treatment (type of surgery: segmental mastectomy or mastectomy; chemotherapy: yes or no; hormone therapy: yes or no and radiation therapy: yes or no). The false discovery rate method of Benjamini et al. (21) was applied for significance testing to limit the probability of falsepositive findings in view of the large number of SNPs tested. We applied a false discovery rate cut-off of 10% in the overall and stratified analysis. The significant SNPs identified after correction for multiple testing were included with the clinical prognostic variables into a multivariable forward selection Cox regression model (with a threshold P value of <0.05 for the likelihood ratio test). Race/ethnicity, ER/PR status and three treatment groups (no systemic therapy, hormone therapy alone and chemotherapy with or without hormone therapy) were evaluated as effect modifiers of the SNP and DFS association by testing for interaction with the significant SNPs (likelihood ratio test P < 0.05 for the Cox regression multivariable model with and without the interaction term). Stratified analysis was performed where effect modification was observed. Univariate and adjusted multivariable analyses of the association between SNPs and DFS were also performed separately for subgroups defined by race/ethnicity. Finally, Kaplan-Meier survival curves and log-rank tests were used to compare DFS by genotype for the significant SNPs according to treatment group. Linkage disequilibrium (LD) between SNPs in the genes of interest was explored using LD mapping in Haploview (22) . All other analyses were performed using STATA (version 10; StataCorp LP, College Station, TX). SNPs ordered by P value (additive model) with smallest P value at the top.
Results
Study population
A majority of the patients in the study (71.7%) were non-Hispanic Whites. The mean age at diagnosis of breast cancer was 53 years. DFS was significantly influenced by age at diagnosis, disease stage, ER/ PR status, surgery type and hormone therapy in univariate analysis at P < 0.05 (Table I) Ten SNPs were significantly associated with DFS at P < 0.05 in univariate analysis in an additive model. These included eight SNPs in RXRA (rs881658, rs11185659, rs10881583, rs881657, rs7864987, rs11185662, rs7871655, rs10776909) and one in PLAUR (rs4251864) and GC (rs3733359). Of these, five SNPs in RXRA, and one PLAUR SNP, were significantly associated with DFS after correction for multiple comparisons (Table II) . The five RXRA SNPs associated with DFS in univariate analysis were in an area of high LD (D′ > 0.8) (Figure 1 ).
Multivariable analysis of SNPs and breast cancer DFS
There was no evidence of an interaction between the six SNPs significant in the univariate analysis and ER/PR status or race. However, there was evidence of an interaction between each of the five RXRA SNPs and treatment group (likelihood ratio test P < 0.05). In the multivariable Cox regression model, including SNPs and clinical covariates significant in the univariate analysis and stratified by treatment group, only one RXRA SNP: rs10881583 (P = 0.02) was associated with poorer DFS among patients who did not receive systemic therapy. Among patients who received chemotherapy, RXRA SNPs: rs881658 (P < 0.001), rs11185659 (P < 0.001), rs10881583 (P < 0.001), rs881657 (P < 0.001) and rs7864987 (P < 0.001) were associated with poorer DFS; and RXR SNPs: rs10881583 (P < 0.001) and rs881657 (P = 0.02) were associated with improved DFS in hormone therapy alone treated patients. The RXRA SNPs largely predicted for poorer DFS in the chemotherapy with or without hormone therapy group and for improved DFS among patients treated with hormone therapy alone (Table III) . The association with poorer survival was observed even when the analysis was restricted to a subgroup who received chemotherapy without hormone treatment (results not shown).
The association between SNPs and breast cancer DFS was also evaluated separately for White, African American and Hispanic patients adjusted for significant prognostic variables (Table IV) . Four of the RXRA SNPs and one PLAUR SNP significant in the overall sample were also significant in Whites, although the P values were attenuated, possibly due to the smaller sample size (Table  IV) . Among African Americans, two SNPs in VDR, rs11574026 and rs4516035, were statistically significant while allowing for multiple comparison along with two additional SNPs in VDR and two SNPs in RXRA that were significant at a nominal P value <0.05. PLAUR: rs344781 was significantly associated with DFS in Hispanics, in addition to three RXRA SNPs associated at P < 0.05. SNPs associated with DFS by race/ethnicity were in the same genes-PLAUR and RXRA for Whites and Hispanics with some degree of overlap (RXRA: rs11185659 and RXRA: rs7864987). Because of the small sample size of each race/ethnicity group, we were unable to evaluate for an interaction between the significant SNPs and treatment group.
Survival analysis of unfavorable RXRA SNPs
Overall, genotypes of the five RXRA SNPs that were significantly associated with breast cancer DFS were in an area of LD. Therefore, Kaplan-Meier curves for one representative RXRA SNP: rs10881583 are presented in Figure 2 . In survival analysis by treatment group, the effect of the representative RXRA SNP: rs10881583 on DFS was predominately evident in the chemotherapy group (log-rank test P < 0.001) but not in the no systemic therapy or hormone therapy alone groups (log-rank test P >0.05). Patients who received chemotherapy with or without hormone therapy and had no mutant alleles of rs10881583 (n = 258) had the best DFS (75% of the patients had DFS of 13.0 years, median −50% DFS not reached), patients with one mutant allele (n = 207) had intermediate DFS (75% of patients had DFS of 7.1 years, median not reached) and patients with two mutant alleles (n = 75) had the worst DFS (75% of the patients had DFS of 4.5 years, and median 12.7 years).
Discussion
We examined the association between genetic variants in vitamin D-related genes and breast cancer DFS and found that six SNPs, five in RXRA (rs881658, rs11185659, rs10881583, rs881657 and rs7864987) and one in PLAUR (rs4251864) were associated with 
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breast cancer DFS in univariate analysis after correction for multiple comparisons. There was evidence of a statistically significant interaction between the RXRA SNPs and treatment group. In the multivariable Cox regression model stratified by treatment group, RXRA SNPs: 10881583, 881657, 881657, 881658, 11185659 and 7864987 were significantly associated with poorer DFS in the chemotherapy group. Although not all RXRA SNPs were significantly associated with DFS in the hormone therapy alone group, RXRA SNPs rs10881583 and rs881657 had an inverse association with DFS in this treatment group. There were race-/ethnicity-specific differences in the SNPs that were nominally associated with DFS; SNPs in RXRA and PLAUR were significantly associated with DFS among non-Hispanic Whites and Hispanics but only SNPs in RXRA and VDR were associated with DFS among African Americans. Interestingly, we observed a significant degree of LD in the RXRA gene between SNPs that were significant in the overall sample and in specific race/ethnicities. Although the LD map for PLAUR does not show areas of high LD with rs4251864, the SNP (PLAUR: rs344781) that was associated with DFS among Hispanics is in substantial LD with rs4251864 (D′ = 0.66).
RXRA, located on chromosome 9q34 (23) , is one of three RXRs (α, β and γ) in the steroid/thyroid hormone nuclear receptor superfamily involved in retinoic acid-mediated gene activation (24) . RXRs (form homodimers or heterodimers with many other nuclear receptors including VDR to regulate transcription by binding to promoters of specific target genes (25) . The RXR have major roles in regulating genes controlling cell proliferation, differentiation and apoptosis by forming heterodimers with the retinoic acid receptors, thyroid hormone receptors, VDR and other nuclear receptors, and are increasingly being considered mediators of a wide range of signaling pathways (26) . In our study, although multiple SNPs in RXRA were (29) and colorectal cancer progression possibly mediated via RXRA suppression and aberrant β-catenin expression (30) . RXRs are potential targets for development of chemoprevention agents because ligands that activate RXRs display potent anticarcinogenic activities (31) . In this context, RXR-selective retinoids have been shown in animal models to suppress the development of breast cancer (32) . Interestingly, specific RXRA SNPs were associated with an improvement in DFS among patients treated with hormone therapy alone (tamoxifen). Although there is no available evidence that tamoxifen binds with RXRs, it is feasible that tamoxifen activation of extracellular signal-regulated kinase/mitogen-activated protein kinase function through cytoplasmic ER could in turn affect RXR phosphorylation and its activity (33) (34) (35) . The biological mechanisms or pathways underlying the association between breast cancer prognosis and RXRA will be a subject for future investigation. PLAUR is a plausible candidate gene for influencing DFS because expression of the encoded protein, urokinase plasminogen activator receptor, has been shown to correlate with increased metastasis in tumor cells (36) . The plasminogen activator system catalyzes the degradation of major extracellular matrix components, allowing for tumor cell migration and tumor progression, a process that may be further modulated by vitamin D3 (37) . Vitamin D-binding proteinmacrophage activating factor, a potent inhibitor of tumor growth, has also been linked to urokinase plasminogen activator receptor expression in tumor cells (38) . Ultimately, the prognosis of breast cancer is determined by tumor metastasis, and high levels of urokinase plasminogen activator and urokinase plasminogen activator receptor expression in breast tumors have been linked to poor relapse-free survival and poorer overall survival in breast cancer (39, 40) .
In the literature, VDR polymorphisms Fok1: rs2228570, Bsm1: rs1544410, Apa1: rs7975232 and Taq1: rs731236 are the vitamin D-related SNPs most studied for an association with breast cancer risk, but the associations overall have not been strong and have varied by ethnic subgroups [reviewed in (41) ]. Similarly, in a comprehensive review of the relationship between polymorphisms in selected vitamin D pathway genes (VDR, CYP27B1, CYP24A1 and GC) and breast cancer risk, there were no consistent associations (6) . There is limited evidence for an association between vitamin D pathway SNPs and breast cancer prognosis (15) . However, VDR polymorphisms have been reported to influence prognosis of colorectal (42) , lung (43) , and head and neck squamous cell carcinoma (44) . In the VDR gene, SNPs Bsm1, Apa1 and Taq1 lie in a region of strong LD, but only Bsm1 was directly genotyped in our study and this SNP was not associated with DFS in the overall sample or in subgroup analysis by race/ethnicity. However, four SNPs in VDR (rs11574026, rs4516035, rs11168293 and 11168292) were associated with DFS among African Americans, and all four SNPs were in a haplotype block in strong LD with each other. Furthermore, rs4516035, a SNP in the flanking 5′ untranslated region (UTR) of VDR was also in LD with the Bsm1, Apa1 and Taq1 SNP block (LD plot generated in Haploview using the Hapmap Yoruban sample from Nigeria as reference: data not shown). Our data suggest that the VDR gene may also influence breast cancer prognosis, albeit only in African Americans.
Two recent genome-wide association studies (45, 46) have tested the hypothesis that common genetic variants may influence circulating vitamin D levels. We examined our data to determine whether known genetic variants that influence vitamin D levels were associated with breast cancer DFS. One of the SNPs identified by both genome-wide association studies was rs2282679 in the GC gene. Although this SNP was not genotyped in our sample, another GCtagging SNP, rs705117, in complete LD with rs2282679 was not significantly associated with DFS.
A major strength of this study is the comprehensive analysis of polymorphisms in several known vitamin D-related genes that may influence breast cancer prognosis in a large sample of breast cancer patients. Our cohort consisted of an ethnically diverse population and the women were followed up over a long period of time (median follow-up 9.5 years) for breast cancer outcomes. In our analyses, we adjusted for important clinical variables that could confound the effect of the genetic variants on DFS. We also allowed for correction for false-positive results due to multiple comparisons by setting a higher P value threshold for significance. A limitation of the study is that levels of circulating 25(OH)D of the patients were not measured because serum samples were not available. Furthermore, in the analysis stratified by race/ethnicity, the numbers of African American (n = 141) and Hispanic women (n = 117) analyzed were small, and it is possible that the ethnicity-specific associations reported could be due to chance and should be assessed in further, larger studies. Interestingly, in the stratified analysis by race/ethnicity, although we found that different top SNPs were associated with DFS in White, 
African American and Hispanic patients, often the SNPs within the same gene were in LD with each other. Other limitations include potential genotyping errors for the SNPs that deviated from Hardy-Weinberg Equilibrium. For example, VDR: rs11574026 associated with DFS among African Americans deviated from Hardy-Weinberg Equilibrium in both African Americans and Hispanics, and PLAUR: rs4251864 associated with DFS in the overall sample and in non-Hispanic Whites was in Hardy-Weinberg Equilibrium in non-Hispanic Whites but not in African Americans. We also found that genotyping call rates were slightly different for DNA extracted from blood or buccal samples versus paraffinembedded tissue, but we did not assess concordance by sample type, for example, FFPE and peripheral lymphocytes from the same individual. Finally, we did not perform analyses according to tumor subtype, which may also modify the results, although there was no evidence of interaction of the top SNPs with ER/PR status.
In conclusion, our results suggest a role of RXRA and PLAUR gene polymorphisms in breast cancer prognosis, and validation using other populations of breast cancer patients is warranted. The association of RXRA SNPs with poorer DFS in patients treated with chemotherapy but improved DFS in patients treated with hormone therapy alone in particular warrants further investigation for potential clinical application. Similarly, investigation into the biological mechanisms through which circulating vitamin D levels and genetic variants in vitamin D pathway genes influence breast cancer prognosis is needed and may provide important information that could be used for risk stratification of breast cancer patients. 
